Northern Trust
MLYS icon

Northern Trust’s Mineralys Therapeutics MLYS Stock Holding History

Northern Trust’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
442,874
+143,011
+48% +$4.19M ﹤0.01% 1969
2025
Q4 		$10.9M Sell
299,863
-90,944
-23% -$3.65M ﹤0.01% 2039
2025
Q3 		$14.8M Buy
390,807
+51,782
+15% +$1.12M ﹤0.01% 1883
2025
Q2 		$4.59M Buy
339,025
+73,969
+28% +$1.07M ﹤0.01% 2506
2025
Q1 		$4.21M Buy
265,056
+18,943
+8% +$218K ﹤0.01% 2512
2024
Q4 		$3.03M Buy
246,113
+1,688
+0.7% +$22.1K ﹤0.01% 2791
2024
Q3 		$2.96M Buy
244,425
+76,624
+46% +$928K ﹤0.01% 2764
2024
Q2 		$1.96M Buy
167,801
+21,680
+15% +$273K ﹤0.01% 2908
2024
Q1 		$1.89M Sell
146,121
-3,659
-2% -$45.2K ﹤0.01% 2990
2023
Q4 		$1.29M Buy
149,780
+37,865
+34% +$297K ﹤0.01% 3217
2023
Q3 		$1.06M Sell
111,915
-599
-0.5% -$7.81K ﹤0.01% 3273
2023
Q2 		$1.92M Buy
112,514
+12,037
+12% +$180K ﹤0.01% 3030
2023
Q1 		$1.57M Buy
+100,477
New +$1.69M ﹤0.01% 3044

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Northern Trust's MLYS Position: Q1 2026 in Review

Northern Trust increased its Mineralys Therapeutics (MLYS) stake by 48% in Q1 2026, buying an estimated $4.19M and bringing the position to 442,874 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #1969.

Northern Trust first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $14.8M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Northern Trust held 442,874 shares of Mineralys Therapeutics worth $12M as of Q1 2026.
  • Northern Trust bought 143,011 Mineralys Therapeutics shares in Q1 2026, an estimated $4.19M.
  • Mineralys Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1969 holding.
  • Northern Trust first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Northern Trust's Mineralys Therapeutics position peaked at $14.8M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.